Search results
Results from the WOW.Com Content Network
Management of tuberculosis refers to techniques and procedures utilized for treating tuberculosis (TB), or simply a treatment plan for TB.. The medical standard for active TB is a short course treatment involving a combination of isoniazid, rifampicin (also known as Rifampin), pyrazinamide, and ethambutol for the first two months.
Styblo refined "a treatment system of checks and balances that provided high cure rates at a cost affordable for most developing countries." This increased the proportion of people cured of TB from 40% to nearly 80%, costing up to $10 per life saved and $3 per new infection avoided. [3]
[3] [4] [5] Those at high risk include household, workplace, and social contacts of people with active TB. [4] Treatment requires the use of multiple antibiotics over a long period of time. [1] Antibiotic resistance is a growing problem, with increasing rates of multiple drug-resistant tuberculosis (MDR-TB). [1]
The current clinical classification system for tuberculosis (TB) is based on the pathogenesis of the disease. [1] Health care providers should comply with local laws and regulations requiring the reporting of TB. All persons with class 3 or class 5 TB should be reported promptly to the local health department. [2]
This was soon followed by the Lung Center of the Philippines, which was constructed under the guidance of Health Minister Dr. Enrique Garcia. With a shift to a parliamentary form of government, the Department of Health was transformed into the Ministry of Health on June 2, 1978, with Dr. Clemente S. Gatmaitan as the first health minister.
The Insular Board of Health was given the power to draft legislation for sanitary and medical practices in the Philippines. They were tasked with studying diseases and prevention methods, as well as overseeing public health. [17] The Board of Health made strategies to counter many diseases like leprosy.
Lengthier treatment, often in hospitals, substantially increases health care costs as well as the economic burden on families and societies. The cost of treating a single case of multidrug-resistant TB (MDR-TB) or extensively drug-resistant TB (XDR-TB) can be thousands of times more expensive than treating drug-sensitive TB. [7]
In a recently published metaanalysis, [26] with data from both developed and developing countries, QuantiFERON-TB Gold In Tube had a pooled sensitivity for active TB of 81% and specificity of 99.2%, whereas T-SPOT.TB had a pooled sensitivity of 87.5% and specificity of 86.3%. In head-to-head comparisons, the sensitivity of IGRAs surpassed TST.